Innovative technology providing groundbreaking drug solutions
Originating from world-recognised, research-led Universities
Targeted technologies yielding greater efficacy with fewer side effects
ICT01-2588 is a targeted vascular disrupting agent, developed by the Institute of Cancer Therapeutics with funding from Cancer Research UK, Yorkshire Cancer Research and University of Bradford.
ICT03-Es5 is a targeted, bio-reductive cytotoxic agent, developed by the University of Salford and the Patterson Institute, University of Manchester.
ICT04-CYP is a targeted, cyp-activated chemotoxin, developed by the De Montford University (Leicester).
Highly experienced team drawn from commercial, scientific and regulatory backgrounds